title: [Advance in microRNAs and EGFR-TKIs secondary resistance research in non-small cell lung cancer].
abstract: In recent years, in non-small cell lung cancer (NSCLC) targeted therapy, especially in patients with epidermal growth factor receptor (EGFR) mutations, EGFR-tyrosine kinase inhibitors (TKI) more and more come into the clinical treatment, but EGFR-TKI resistance not only influence the drug sensitivity, appear even disease progression, become the main bottleneck of its curative effect. MicroRNAs (miRNAs) is a non coding RNA and protein involved in regulating gene expression in the transcription level. Recent studies found that miRNAs involved in EGFR-TKIs resistance, which affect the sensitivity of tumor cells to treatment. In this paper, we reviewed briefly advance in miRNAs and EGFR-TKIs secondary resistance research in NSCLC.
authors.affiliation: Graduate Student of Hebei Medical University, Shijiazhuang 050000, China.
authors.forename: Xiaoyang
authors.initials: X
authors.lastname: Duan
authors.affiliation: Department of Medical Oncology,  Hebei Province Cancer Hospital, Shijiazhuang 050000, China.
authors.forename: Jian
authors.initials: J
authors.lastname: Shi
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics*; D066246:ErbB Receptors / Q000235:genetics*; D006801:Humans; D008175:Lung Neoplasms / Q000201:enzymology* / Q000235:genetics*; D035683:MicroRNAs / Q000235:genetics*
chemical_list: D035683:MicroRNAs; D066246:ErbB Receptors